share_log

FPH Upgrades Earnings Guidance Driven by Currency Rate Movements

FPH Upgrades Earnings Guidance Driven by Currency Rate Movements

受匯率變動的推動,FPH上調了收益指引
sharecafe ·  03/22 05:43

Good news and bad news on Friday from NZ-based Fisher and Paykel Healthcare.

總部位於新西蘭的費舍爾和Paykel Healthcare週五有好消息和壞消息。

Ahead of the March 31 end to its financial year, the company has revealed an upgrade to guidance but it also disclosed that it is facing a hit from a potential fall in property values (which will be a non-cash item in the results).

在3月31日財政年度結束之前,該公司公佈了對指導方針的上調,但也透露說,它正面臨房地產價值可能下跌的打擊(這將是業績中的非現金項目)。

The company told exchanges on both sides of the Tasman that it had lifted its revenue and earnings outlook for the about to finish financial year.

該公司告訴塔斯曼河兩岸的交易所,它已經上調了即將結束的財政年度的收入和收益展望。

The company said its full year guidance previously provided on November 29 last year was based on a "NZ:US exchange rate of 58 cents, was for operating revenue to be approximately $1.7 billion and net profit after tax to be in the range of approximately $250 million to $260 million."

該公司表示,其先前於去年11月29日提供的全年指引是基於 “新西蘭與美國的匯率爲58美分,營業收入約爲17億美元,稅後淨利潤約在2.5億美元至2.6億美元之間。”

"Now, assuming a NZ:US exchange rate of approximately 61 cents for the balance of the financial year, the company expects full year operating revenue to be approximately $1.73 billion and underlying profit after tax (excluding any fair value changes) to be in the range of approximately $260 million to $265 million

該公司週五解釋說:“現在,假設本財年剩餘時間內新西蘭與美國的匯率約爲61美分,該公司預計全年營業收入約爲17.3億美元,稅後基礎利潤(不包括任何公允價值變動)將在約2.6億美元至2.65億美元之間。

"In the Hospital product group, there has been a continuation of solid demand for our hospital consumables across the product portfolio throughout the second half, which is towards the upper end of our expectations from November," according to CEO, Lewis Gradon.

首席執行官劉易斯·格拉登表示:“在醫院產品組中,整個產品組合中對我們醫院消耗品的需求持續強勁,接近我們自11月以來的預期上限。”

""In OSA masks, we have continued to see strong performance from our Evora Full mask. We have received positive feedback on our revolutionary F&P Solo mask after the recent release in early markets, and we look forward to its introduction in more countries in the coming months."

“” 在 OSA 口罩中,我們繼續看到我們的 Evora Full 口罩的強勁性能。我們的革命性F&P Solo面具最近在早期市場上發佈後,我們收到了積極的反饋,我們期待在未來幾個月內將其推廣到更多國家。”

But Fisher and Paykel also warned however that its property valuations are likely to be impaired - with the extent of the impact on 2024 earnings unknown at this stage.

但是,費舍爾和佩克爾也警告說,其房地產估值可能會受到損害——現階段對2024年收益的影響程度尚不清楚。

"The company will shortly be commencing a scheduled valuation of the properties that it owns in East Tmaki and Karaka, Auckland and in Tijuana, Mexico as at 31 March 2024.

“該公司不久將開始對截至2024年3月31日其在東塔基和卡拉卡、奧克蘭和墨西哥蒂華納擁有的房產進行預定估值。

"In preliminary discussions we have been advised that the higher interest rate environment and current zoning status of our land in Karaka will likely have an adverse impact on the Karaka property valuation.

“在初步討論中,我們被告知,較高的利率環境和我們在卡拉卡的土地目前的分區狀況可能會對卡拉卡的房地產估值產生不利影響。

"Any reduction in the value of the Karaka land would be recognised as a non-cash accounting adjustment in the income statement and will impact our reported net profit after tax for the year. The quantum of any potential reduction in value is currently unknown, and our FY24 earnings guidance excludes this non-cash effect," he said.

“卡拉卡土地價值的任何減少都將在損益表中被確認爲非現金會計調整,並將影響我們報告的當年稅後淨利潤。目前尚不清楚任何潛在價值減少的幅度,我們的24財年收益指引不包括這種非現金效應,” 他說。

"Asset valuations will be undertaken by independent valuers, are subject to final audit and will be confirmed in the financial results for the year ending 31 March 2024, expected to be announced on 29 May 2024.

“資產估值將由獨立估值師進行,有待最終審計,並將在預計於2024年5月29日公佈的截至2024年3月31日的年度財務業績中得到確認。

"Development of the new campus will occur over the next 30 to 40 years. We expect to submit our application for re-zoning of the Karaka land next financial year and the approvals to be granted over the coming years, Grasdon added.

“新校區的開發將在未來30至40年內進行。格拉斯登補充說,我們預計將在下個財政年度提交卡拉卡土地重新分區的申請,並在未來幾年內獲得批准。

1x1.png?futu_img_keep_extra_domain=1

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論